Specialist Pharmacy NICE Bites Mar Service



March 2020: No. 126

A summary of prescribing recommendations from NICE guidance

This edition includes one guideline.

Impetigo: antimicrobial prescribing NICE NG153; February 2020

This guideline sets out an antimicrobial prescribing strategy for adults, young people and children aged 72 hours and over with impetigo, a contagious, bacterial infection of the superficial layers of the skin. It aims to optimise antibiotic use and reduce antibiotic resistance.

See the <u>two-page visual summary</u> of recommendations, including tables to support prescribing decisions.

Definition of terms

Non-bullous impetigo is characterised by thin-walled vesicles or pustules that rupture quickly, forming a goldenbrown crust.

Bullous impetigo is characterised by the presence of fluid-filled vesicles and blisters often with a diameter of over 1cm that rupture, leaving a thin, flat, yellow-brown crust.

Decolonisation is the use of topical treatments (antiseptic body wash, nasal ointment or a combination of both) and personal hygiene measures to remove the bacteria causing the infection from the body.

Treatment

 Advise people with impetigo, and their parents or carers if appropriate, about good hygiene measures to reduce the spread of impetigo to other areas of the body and to other people.

Impetigo in people who are not systemically unwell or at high risk of complications

Localised non-bullous impetigo

- Consider hydrogen peroxide 1% cream. Although other topical antiseptics are available for treating superficial skin infections, no evidence was found for using them to treat impetigo.
- If hydrogen peroxide 1% cream is unsuitable, offer a short course of a topical antibiotic (see Choice of antimicrobial).

Widespread non-bullous impetigo

- Offer a short course of a topical or oral antibiotic (see Choice of antimicrobial). Take into account:
 - topical and oral antibiotics are both effective at treating impetigo,,
 - > preferences of the person and, if appropriate, their parents or carers, including the practicalities of administration (particularly to large areas) and possible adverse effects,
 - > previous use of topical antibiotics, because antimicrobial resistance can develop rapidly with extended or repeated use.

Bullous impetigo

• Offer a short course of an oral antibiotic (see Choice of antimicrobial).

Impetigo in people who are systemically unwell or at high risk of complications

 Offer a short course of an oral antibiotic for people with bullous or non-bullous impetigo if they are systemically unwell or at high risk of complications.

Please go to <u>www.nice.org.uk</u> to check for any recent updates to this guidance.

Combination treatment

• Do not offer combination treatment with a topical and oral antibiotic to treat impetigo.

Advice

 Advise people with impetigo, and their parents or carers if appropriate, to seek medical help if symptoms worsen rapidly or significantly at any time, or have not improved after completing a course of treatment.

Reassessment and further treatment

- Reassess people with impetigo if their symptoms worsen rapidly or significantly at any time or have not improved after completing a course of treatment.
- When reassessing people with impetigo, take account of:
 > other possible diagnoses, such as herpes simplex
 - any symptoms or signs suggesting a more serious illness or condition, such as cellulitis
 - previous antibiotic use, which may have led to resistant bacteria.
- For people with impetigo that is worsening or has not improved after treatment with hydrogen peroxide 1% cream, offer:
 - \succ a short course of a topical antibiotic if the impetigo remains localised, OR
 - a short course of a topical or oral antibiotic (see Choice of antimicrobial) if the impetigo has become widespread.
- For people with impetigo that is worsening or has not improved after completing a course of topical antibiotics:
 - offer a short course of an oral antibiotic (see Choice of antimicrobial), AND

> consider sending a skin swab for microbiological testing.

- For people with impetigo that is worsening or has not improved after completing a course of oral antibiotics, consider sending a skin swab for microbiological testing.
- For people with impetigo that recurs frequently:
 - > send a skin swab for microbiological testing, AND
 - consider taking a nasal swab and starting treatment for decolonisation.
- If a skin swab has been sent for microbiological testing:
 - review the choice of antibiotic when results are available, AND
 - change the antibiotic according to results if symptoms are not improving, using a narrow-spectrum antibiotic if possible.

Referral or seeking specialist advice

- Refer to hospital:
 - people with impetigo and any symptoms or signs suggesting a more serious illness or condition (for example, cellulitis),
 - people with widespread impetigo who are immunocompromised.
- Consider referral or seeking specialist advice for people with impetigo if they:
- have bullous impetigo, particularly in babies (aged 1 year and under),
- > have impetigo that recurs frequently,
- > are systemically unwell,
- > are at high risk of complications.



Bulletin editor: Karoline Brennan

North West Medicines Information Centre offers a free medicines enquiry answering service 8.30am to 5pm, Monday to Friday. Tel: 0151 794 8113. Email: <u>nwmedinfo@nhs.net</u>



NICE Bites

Table 2: Antimicrobials for children and young people <18

Impetigo: antimicrobial prescribing......continued NICE NG153; 2020

years

Choice of antimicrobial

Table 1: Antimicrobials for adults ≥ 18 years

Dosage and course length² Dosage and course length² Antimicrobial¹ Antimicrobial¹ **Topical antiseptic Topical antiseptic** Apply two or three times a day Apply two or three times a day for Hydrogen peroxide 1%³ Hydrogen peroxide 1%³ for 5 days 5 days First-choice topical antibiotic⁵ if hydrogen peroxide First-choice topical antibiotic⁵ if hydrogen peroxide unsuitable (e.g. if impetigo is around eyes) or unsuitable (e.g. if impetigo is around eyes) or ineffective ineffective Apply three times a day for 5 Apply three times a day for 5 Fusidic acid 2% Fusidic acid 2% days days Alternative topical antibiotic⁵ if fusidic acid Alternative topical antibiotic⁵ if fusidic acid resistance suspected or confirmed resistance suspected or confirmed Apply three times a day for 5 Apply three times a day for 5 Mupirocin 2%⁶ Mupirocin 2% days davs First-choice oral antibiotic First-choice oral antibiotic 500mg four times a day for 5 1 month to 1 year, 62.5mg to Flucloxacillin 125mg four times a day for 5 days days⁴ Alternative oral antibiotics if penicillin allergy or Flucloxacillin (oral 2 to 9 years, 125mg to 250mg flucloxacillin unsuitable solution or capsules⁷) four times a day for 5 days⁴ 250mg twice a day for 5 days^{4,6} Clarithromycin 10 to 17 years, 250mg to 500mg 250mg to 500mg four times a Erythromycin (in pregnancy) four times a day for 5 days⁴ day for 5 days4 Alternative oral antibiotics if penicillin allergy or If MRSA (methicillin-resistant Staphlococcus aureus) flucloxacillin unsuitable (e.g. if oral solution suspected or confirmed – consult local inpalatable and unable to swallow capsules) microbiologist See **BNF for Children** for doses Clarithromycin 1 See BNF for appropriate use and dosing in specific 8 to 17 years, 250mg to 500mg Erythromycin (in populations, e.g. hepatic impairment, renal impairment, four times a day for 5 days⁴ pregnancy) pregnancy and breastfeeding. If MRSA (methicillin-resistant Staphlococcus 2 Oral doses are for immediate-release medicines. aureus) suspected or confirmed – consult local **3** Other topical antiseptics are available for superficial skin microbiologist infections, but no evidence was found for using these in 1 See BNF for <u>Children</u> for appropriate use and dosing in impetiao. specific populations e.g. hepatic impairment, renal **4** A 5-day course is appropriate for most people with impetigo impairment, pregnancy and breastfeeding. Dosing in some but can be increased to 7 days based on clinical judgement, age groups may be off-label. depending on the severity and number of lesions. 2 Oral doses are for immediate-release medicines. The age 5 As with all antibiotics, extended or recurrent use of topical bands apply to children of average size and, in practice, the fusidic acid or mupirocin may increase the risk of developing prescriber will use the age bands in conjunction with other factors such as the severity of the condition being treated and antimicrobial resistance. See BNF for more information. the child's size in relation to the average size of children the 6 Dosage can be increased to 500mg twice a day, if needed for same age. severe infections. 3 Other topical antiseptics are available for superficial skin infections, but no evidence was found for using these in impetigo. **4** A 5-day course is appropriate for most people with impetigo Recommendations - wording used such as 'offer' and but can be increased to 7 days based on clinical judgement, 'consider' denote the strength of the recommendation. depending on the severity and number of lesions. Drug recommendations - the guideline assumes that **5** As with all antibiotics, extended or recurrent use of topical prescribers will use a drug's Summary of Product fusidic acid or mupirocin may increase the risk of developing Characteristics (SPC) to inform treatment decisions. antimicrobial resistance. See BNF for Children for more information. 6 Licenses for use in infants vary between products. See individual Summaries of Product Characteristics for details. 7 See Medicines for Children, Helping your child to swallow Please go to www.nice.org.uk to check for any recent

updates to this guidance.

This bulletin summarises key prescribing points from NICE guidance. Please refer to the full guidance at <u>www.nice.org.uk</u> for further detail. This is an NHS document not to be used for commercial purposes.

tablets.